Market Overview - The market experienced narrow fluctuations with mixed performance among the three major indices. The Shanghai Composite Index rose by 0.01%, the Shenzhen Component fell by 0.11%, and the ChiNext Index increased by 0.26% [1] - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.3 trillion yuan, with over 2,300 stocks rising. A total of 74 stocks hit the daily limit up, while 29 stocks failed to do so, resulting in an overall limit-up rate of 71.84% [1] Sector Performance - The leading sectors in terms of gains included beauty care, IP economy, controllable nuclear fusion, and innovative pharmaceuticals, while the sectors with the largest declines were port shipping, liquor, pork, and coal [1] Historical Highs - A total of 46 stocks reached new historical closing highs, excluding newly listed stocks within the past year. Among these, 22 were from the main board, 11 from the ChiNext, and 6 from the Sci-Tech Innovation Board [1] - The industries with the most stocks hitting historical highs were pharmaceuticals and biology (11 stocks), banking (6 stocks), and basic chemicals (5 stocks) [1] Stock Performance - The average increase for stocks that reached historical highs was 4.92%. Notable stocks that hit the limit up included Baixinglong, Haishike, and Ruoyuchen, while stocks with significant gains included Tongxin Transmission, Leidi Ke, and Luqiao Information [1][2] Institutional Activity - On June 12, institutional investors net bought 34 million yuan worth of stocks, with the top net purchases being Yaoyi Technology, Zhaori Technology, and Qingmu Technology, accounting for 14.61%, 1.74%, and 2.06% of the day's trading volume, respectively [5] - The top net sales by institutions included Limin Co., Ltd., Yongjin Co., Ltd. (rights protection), and Rongchang Bio, with net sales accounting for 2.78%, 12.81%, and 4.01% of the day's trading volume, respectively [5] Important Announcements - Borui Pharmaceutical plans to invest 20 million yuan to acquire a 4.1667% stake in Suzhou Geek Gene Technology Co., Ltd. This transaction is classified as a related party transaction and does not constitute a major asset restructuring [9] - Hengbang Co. received a corrective measure from the Shandong Securities Regulatory Bureau due to a failure to disclose information regarding the criminal investigation of its deputy general manager [9] - Baicheng Pharmaceutical's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan within six months [9]